Guardian Pharmacy Services (NYSE:GRDN) Shares Down 3.6% – Time to Sell?

Guardian Pharmacy Services, Inc. (NYSE:GRDN)’s share price traded down 3.6% during mid-day trading on Tuesday . The stock traded as low as $22.76 and last traded at $22.80. 17,273 shares traded hands during trading, a decline of 91% from the average session volume of 187,614 shares. The stock had previously closed at $23.65.

Analysts Set New Price Targets

Several equities analysts recently commented on GRDN shares. Truist Financial increased their target price on Guardian Pharmacy Services from $22.00 to $24.00 and gave the company a “buy” rating in a report on Friday, November 15th. Raymond James began coverage on Guardian Pharmacy Services in a research note on Monday, October 21st. They set an “outperform” rating and a $21.00 target price for the company. Finally, Stephens started coverage on shares of Guardian Pharmacy Services in a research note on Tuesday, October 22nd. They issued an “overweight” rating and a $21.00 price target on the stock.

Guardian Pharmacy Services Trading Down 5.1 %

The stock has a 50-day simple moving average of $21.32.

Guardian Pharmacy Services (NYSE:GRDN) last released its earnings results on Tuesday, November 12th. The company reported ($2.00) EPS for the quarter, missing the consensus estimate of $0.19 by ($2.19). The firm had revenue of $314.39 million for the quarter, compared to the consensus estimate of $303.21 million. On average, analysts anticipate that Guardian Pharmacy Services, Inc. will post 0.87 EPS for the current year.

Insiders Place Their Bets

In other Guardian Pharmacy Services news, Director Steven D. Cosler purchased 7,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The shares were purchased at an average cost of $21.22 per share, for a total transaction of $148,540.00. Following the completion of the purchase, the director now directly owns 17,713 shares in the company, valued at $375,869.86. This represents a 65.34 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Thomas J. Salentine, Jr. acquired 35,714 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The shares were acquired at an average cost of $14.00 per share, for a total transaction of $499,996.00. Following the acquisition, the director now directly owns 35,714 shares of the company’s stock, valued at $499,996. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here.

Institutional Trading of Guardian Pharmacy Services

Institutional investors have recently added to or reduced their stakes in the stock. Stephens Inc. AR purchased a new position in Guardian Pharmacy Services in the third quarter valued at about $189,000. Virtu Financial LLC acquired a new stake in shares of Guardian Pharmacy Services in the 3rd quarter worth approximately $279,000. Barclays PLC purchased a new position in Guardian Pharmacy Services in the 3rd quarter valued at approximately $311,000. Point72 DIFC Ltd acquired a new position in Guardian Pharmacy Services during the third quarter worth $573,000. Finally, Royce & Associates LP purchased a new stake in Guardian Pharmacy Services during the third quarter worth $1,260,000.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.